Tipton2015 - ASC Diversity and Origin in SLE

Full citation: Tipton CM, Fucile CF, Darce J, Chida A, Ichikawa T, Gregoretti I, Schieferl S, Hom J, Jenks S, Feldman RJ, Mehr R, Wei C, Lee FE, Cheung WC, Rosenberg AF, Sanz I. Diversity, cellular origin and autoreactivity of antibody-secreting cell population expansions in acute systemic lupus erythematosus. Nature Immunology. 2015;16(7):755–765. doi:10.1038/ni.3175

Raw file: [[raw/tipton2015.pdf]]

Summary

This study investigates the diversity, cellular origin, and autoreactivity of the massive antibody-secreting cell (ASC) expansions that characterise acute SLE flares. Using simultaneous deep BCR sequencing (NGS), serum antibody proteomics, and single-cell monoclonal antibody analysis from the same blood draws, the Sanz lab (Emory + Rochester) establishes three major findings: (1) circulating ASCs in SLE flares are surprisingly polyclonal — dominated by non-antigen-specific cells — with disease-associated VH4-34⁺ autoreactive clones punctuating but not dominating the repertoire; (2) ASC SHM rates in SLE are substantially lower than in vaccination responses, consistent with extrafollicular origin; and (3) a newly characterised population of activated naive (acN) B cells is an important and persistent precursor of circulating ASCs, contributing directly to the serum autoantibody pool without requiring somatic hypermutation.

The paper provides the first direct proof in human SLE that naive B cells can differentiate into ASCs via extrafollicular pathways, generating fully autoreactive antibodies from germline-encoded sequences. acN cells persist in circulation for months while continuously seeding new ASC progeny, implying an ongoing naive-to-effector axis that sustains ASC population expansion across flares. The study connects serum protein sequences to ASC clonotypes by proteomics, establishing the causal link between specific circulating B cells and specific serum autoantibodies.

For this wiki, Tipton2015 provides: (a) quantitative SHM benchmarks for EF vs. GC-derived plasmablasts; (b) a defined phenotype for activated naive B cells as EF plasmablast precursors; (c) the CD138⁻/CD138⁺ ASC maturation framework; and (d) ELISPOT evidence for bystander polyclonal ASC activation in disease — all relevant comparators for dengue plasmablast studies.

Study Design

• Type: Cross-sectional with limited longitudinal follow-up (2 patients followed weekly for 4–8 weeks)
• Sample size: n=5 SLE acute flare (primary NGS cohort); n=4 influenza-vaccinated healthy; n=4 tetanus-vaccinated healthy; additional n=46 SLE for ELISPOT validation (9G4); n=6 additional SLE for single-cell monoclonal antibody analysis
• Setting: University of Rochester and Emory University, 2010–2013; patients recruited during moderate-to-severe flares on minimal immunosuppression (hydroxychloroquine ± prednisone ≤10 mg/day or equivalent)
• Population: Adult SLE patients meeting ≥4 ACR classification criteria; healthy adult controls vaccinated with trivalent influenza vaccine or tetanus toxoid; pemphigus vulgaris and IgG4-related disease controls used for VH4-34 specificity analysis

Key Findings

• SLE ASC gate: CD19⁺IgD⁻CD27^hiCD38^hi (as in prior Sanz lab work); up to 40-fold more abundant in SLE flares than in healthy subjects (~15–52% of IgD⁻CD19⁺ B cells vs. ~2% healthy). All circulating ASCs are Ki67⁺ (proliferative plasmablasts); subdivided into CD138⁻ (early) and CD138⁺ (more mature) fractions, which are clonally connected.
• ASC polyclonality: D20 values (number of clones needed to account for 20% of sequences) averaged 199.2 (CD138⁻) and 126.8 (CD138⁺) in SLE vs. 21.1 and 10.9 in vaccinated controls — a ~10-fold difference. This is inconsistent with a simple recall-memory model and supports broad polyclonal activation.
• VH4-34 enrichment in top clones: VH4-34 accounted for 5.9–19.5% of all ASC sequences in SLE but only 1.1–7.6% post-vaccination. In the D20 fraction (top clones), SLE CD138⁻ ASCs averaged 20.7% VH4-34 vs. 2.9% post-vaccination (p<0.01). VH4-34 contributed to clonal expansion in all 5 SLE patients. VH4-34 enrichment was SLE-specific: absent from pemphigus vulgaris and IgG4-related disease ASC expansions.
• Lower SHM in SLE ASCs: Average VH mutation rate 4.98% (SLE) vs. 7.33% (vaccinated controls). Approximately 30–33% of SLE ASC sequences contained <3% VH mutation vs. 10–12% post-vaccination (p<0.05). Two patients (SLE-4 and SLE-5) had 39.8% and 52.9% of ASC sequences with <3% mutation. CDR mutation frequency exceeded framework region mutation frequency in both groups (CDR avg 6.74%, FR 3.15% in SLE), consistent with antigen-driven selection.
• acN cell characterisation: CD19^hi, IgD⁺, CD27⁻, MTG⁺, CD24⁻, CD21⁻, CD38^lo, IgM^lo, CD23⁻ population nearly absent in healthy subjects (<1%) but abundant in SLE flares (20–45% of IgD⁺CD27⁻ cells). Distinguished from transitional B cells by CD24⁻ (transitional are MTG⁺CD24⁺) and from resting naive by MTG⁺ (resting naive are MTG⁻CD24⁺).
• acN → ASC connectivity: Up to 32.5% of acN sequences share clonal identity with co-circulating ASC sequences; 9 of 10 largest acN clones are direct ASC precursors; ratio of naive-to-memory ASC connectivity significantly higher in SLE than vaccination (p<0.05).
• acN persistence: acN cells identified at the single-cell level in one patient were clonally related to ASC clones detected by NGS 4 months earlier. Phylogenetic trees showed unmutated acN precursors (0% SHM) co-existing with ASC progeny carrying up to 21.5% VH mutation — implying months of ongoing diversification from a naive precursor.
• Germline-encoded autoreactivity: ASC clone 652-F6 had zero VH and VL mutations yet showed strong reactivity to ANA (Hep-2 immunofluorescence and ELISA), dsDNA, chromatin, and ribosomal P antigens — directly proving that naive B cells without SHM can differentiate into fully autoreactive ASCs via extrafollicular pathways.
• ELISPOT results: Despite no recent immunization, influenza-specific ASCs were detectable in 0–1.2% of IgG⁺ ASCs in SLE; tetanus-specific in 0–0.65%; undetectable in healthy controls. Even in patients with large ASC expansions, anti-dsDNA + anti-Ro + anti-Sm together accounted for <3% of IgG⁺ ASCs. 9G4⁺ ASCs: median 2.4%, up to 20% of IgG⁺ ASCs.
• Serum proteomics: LC-MS/MS of affinity-purified serum 9G4⁺ antibodies matched 39 sequences to 20 distinct clonotypes in NGS data from the same blood draw; two clonotypes from patient SLE-3 were confirmed to persist in circulation for >8 weeks.

Methods Used

Conventional Flow Cytometry, FACS Sorting, BCR Sequencing, ELISpot, Serum Proteomics

Entities Mentioned

Plasmablast, Activated Naive B Cell, CD19, CD27, CD38, IgD, CD138, CD21, CD24, CD10, CD23, IgM, IgG, IgA, Double-Negative B Cell

Concepts Addressed

Extrafollicular Response, Germinal Center, Somatic Hypermutation, Class Switch Recombination, Memory B Cell

Relevance & Notes

This is the third paper from the Sanz lab (following Wei2007 - DN Memory B Cells in SLE and Anolik2004 - Rituximab and B Cell Abnormalities in SLE). It represents a significant methodological and conceptual advance over both: it uses NGS rather than Sanger sequencing, integrates proteomics, introduces the acN cell as a defined entity, and provides the most direct human evidence yet for extrafollicular naive→ASC differentiation.

For dengue context: the SHM benchmarks established here (<3% mutation in ~30% of SLE ASCs) represent the most quantitatively precise available comparator for EF-derived plasmablasts in human disease. If dengue plasmablast papers report similar low-SHM fractions, that would constitute meaningful evidence for EF dominance in acute dengue. The acN cell phenotype also provides a testable gating strategy: if dengue acute-phase blood contains CD19^hi, CD21⁻, CD24⁻, MTG⁺ cells within the IgD⁺CD27⁻ gate, those would be candidate EF plasmablast precursors.

9G4/VH4-34 data treated as SLE background: Findings specific to VH4-34 clonal expansion and 9G4 autoantibody production are noted in this source page but not propagated to entity/concept pages, per curator direction (decision [2026-05-02]).

Limitation: The study uses sorted populations for NGS but samples only peripheral blood — it cannot address what happens in lymph nodes or spleen where EF reactions and GC reactions actually occur. The interpretation of circulating naive/acN connectivity to ASCs necessarily underestimates the true naive cell contribution because the lag between naive cell activation and ASC expansion means clonally related naive cells will often have been replaced by the time sampling occurs.

Questions Raised

• Does the acN cell population (CD19^hi, MTG⁺, CD24⁻, CD21⁻, CD23⁻) expand in acute dengue infection? Is it detectable in acute-phase PBMC samples using these markers?
• What is the SHM distribution of circulating plasmablasts in acute dengue — does the <3% SHM fraction reach the 30% threshold seen in SLE flares, consistent with predominant EF origin?
• Are the majority of dengue antigen-specific antibodies generated by the acute-phase plasmablast wave derived from naive cells (as in SLE) or from pre-existing cross-reactive memory cells (as in vaccine recall)?
• Can serum proteomics (as used here) be applied to dengue patient samples to directly link circulating plasmablast clones to dengue-specific serum antibodies?